In this report, we employed the solid-phase synthetic approach to prepare variously substituted dihydropteridinones, tetrahydropyrrolopteridinones, and pyrimidodiazepinones, using a versatile building block-4,6-dichloro-5-nitropyrimidine. All these compounds are pharmacologically significant scaffolds of the great importance of medicinal chemists. The fast and efficient synthetic methodology is highly desirable for defining their structure-activity relationship (SAR) and optimizing pharmacokinetic properties. Our research efforts utilize simple synthetic methods to generate a library of analogues for future SAR studies. The efficiency of our approach was exemplified in various pteridinones as well as pyrimidodiazepinones.

Department of Organic Chemistry Faculty of Science Palacký University 17 listopadu 12 771 46 Olomouc Czech Republic

Zobrazit více v PubMed

Li Q., Yang H.K., Sun Q., You W.W., Zhao P.L. Design, Synthesis and Antiproliferative Activity of Novel Substituted 2-Amino-7,8-Dihydropteridin-6(5H)-One Derivatives. Bioorg. Med. Chem. Lett. 2017;27:3954–3958. doi: 10.1016/j.bmcl.2017.07.076. PubMed DOI

Bowers S., Truong A.P., Ye M., Aubele D.L., Sealy J.M., Neitz R.J., Hom R.K., Chan W., Dappen M.S., Galemmo R.A., et al. Design and Synthesis of Highly Selective, Orally Active Polo-like Kinase-2 (Plk-2) Inhibitors. Bioorg. Med. Chem. Lett. 2013;23:2743–2749. doi: 10.1016/j.bmcl.2013.02.065. PubMed DOI

Budin G., Yang K.S., Reiner T., Weissleder R. Bioorthogonal Probes for Polo-like Kinase 1 Imaging and Quantification. Angew. Chem. Int. Ed. 2011;50:9378–9381. doi: 10.1002/anie.201103273. PubMed DOI PMC

Liu S., Yosief H.O., Dai L., Huang H., Dhawan G., Zhang X., Muthengi A.M., Roberts J., Buckley D.L., Perry J.A., et al. Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. J. Med. Chem. 2018;61:7785–7795. doi: 10.1021/acs.jmedchem.8b00765. PubMed DOI PMC

Rudolph D., Steegmaier M., Hoffmann M., Grauert M., Baum A., Quant J., Haslinger C., Garin-Chesa P., Adolf G.R. BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity. Clin. Cancer Res. 2009;15:3094–3102. doi: 10.1158/1078-0432.CCR-08-2445. PubMed DOI

Rosse G. Dihydropteridinone Inhibitors of BRD4. ACS Med. Chem. Lett. 2016;7:131. doi: 10.1021/acsmedchemlett.5b00381. PubMed DOI PMC

Jeon M.Y., Min K.J., Woo S.M., Seo S.U., Kim S., Park J.W., Kwon T.K. Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of C-FLIP Expression. Int. J. Mol. Sci. 2017;18:2568. doi: 10.3390/ijms18122568. PubMed DOI PMC

Kiryanov A., Natala S., Jones B., McBride C., Feher V., Lam B., Liu Y., Honda K., Uchiyama N., Kawamoto T., et al. Structure-Based Design and SAR Development of 5,6-Dihydroimidazolo[1,5-f]Pteridine Derivatives as Novel Polo-like Kinase-1 Inhibitors. Bioorg. Med. Chem. Lett. 2017;27:1311–1315. doi: 10.1016/j.bmcl.2016.10.009. PubMed DOI

Hou Y., Zhu L., Li Z., Shen Q., Xu Q., Li W., Liu Y., Gong P. Design, Synthesis and Biological Evaluation of Novel 7-Amino-[1,2,4]Triazolo[4,3-f]Pteridinone, and 7-Aminotetrazolo[1,5-f]Pteridinone Derivative as Potent Antitumor Agents. Eur. J. Med. Chem. 2019;163:690–709. doi: 10.1016/j.ejmech.2018.12.009. PubMed DOI

Li Z., Xu L., Zhu L., Zhao Y., Hu T., Yin B., Liu Y., Hou Y. Design, Synthesis and Biological Evaluation of Novel Pteridinone Derivatives Possessing a Hydrazone Moiety as Potent PLK1 Inhibitors. Bioorg. Med. Chem. Lett. 2020;30:127329. doi: 10.1016/j.bmcl.2020.127329. PubMed DOI

Zhan M.M., Yang Y., Luo J., Zhang X.X., Xiao X., Li S., Cheng K., Xie Z., Tu Z., Liao C. Design, Synthesis, and Biological Evaluation of Novel Highly Selective Polo-like Kinase 2 Inhibitors Based on the Tetrahydropteridin Chemical Scaffold. Eur. J. Med. Chem. 2018;143:724–731. doi: 10.1016/j.ejmech.2017.11.058. PubMed DOI

Thrum S., Lorenz J., Moessner J., Wiedmann M. Polo-like Kinase 1 Inhibition as a New Therapeutic Modality in Therapy of Cholangiocarcinoma. Anticancer Res. 2011;31:3289–3299. PubMed

Watts E., Heidenreich D., Tucker E., Raab M., Strebhardt K., Chesler L., Knapp S., Bellenie B., Hoelder S. Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. J. Med. Chem. 2019;62:2618–2637. doi: 10.1021/acs.jmedchem.8b01947. PubMed DOI PMC

Chiu Y.L., Dinesh C.U., Chu C.Y., Ali A., Brown K.M., Cao H., Rana T.M. Dissecting RNA-Interference Pathway with Small Molecules. Chem. Biol. 2005;12:643–648. doi: 10.1016/j.chembiol.2005.04.016. PubMed DOI

Chen L., Yap J.L., Yoshioka M., Lanning M.E., Fountain R.N., Raje M., Scheenstra J.A., Strovel J.W., Fletcher S. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med. Chem. Lett. 2015;6:764–769. doi: 10.1021/acsmedchemlett.5b00084. PubMed DOI PMC

Nie Z., Feher V., Natala S., McBride C., Kiryanov A., Jones B., Lam B., Liu Y., Kaldor S., Stafford J., et al. Discovery of TAK-960: An Orally Available Small Molecule Inhibitor of Polo-like Kinase 1 (PLK1) Bioorg. Med. Chem. Lett. 2013;23:3662–3666. doi: 10.1016/j.bmcl.2013.02.083. PubMed DOI

Menne S., Tumas D.B., Liu K.H., Thampi L., AlDeghaither D., Baldwin B.H., Bellezza C.A., Cote P.J., Zheng J., Halcomb R., et al. Sustained Efficacy and Seroconversion with the Toll-like Receptor 7 Agonist GS-9620 in the Woodchuck Model of Chronic Hepatitis B. J. Hepatol. 2015;62:1237–1245. doi: 10.1016/j.jhep.2014.12.026. PubMed DOI PMC

Lanford R.E., Guerra B., Chavez D., Giavedoni L., Hodara V.L., Brasky K.M., Fosdick A., Frey C.R., Zheng J., Wolfgang G., et al. GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology. 2013;144:1508–1517. doi: 10.1053/j.gastro.2013.02.003. PubMed DOI PMC

Baxter A.D., Boyd E.A., Cox P.B., Loh V., Jr., Monteils C., Proud A. 4,6-Dichloro-5-Nitropyrimidine: A Versatile Building Block for the Solid-Phase Synthesis of Dihydropteridinones. Tetrahedron Lett. 2000;41:8177–8181. doi: 10.1016/S0040-4039(00)01427-1. DOI

Nagashima T., Zhang W. Solution-Phase Parallel Synthesis of an N-Alkylated Dihydropteridinone Library from Fluorous Amino Acids. J. Comb. Chem. 2004;6:942–949. doi: 10.1021/cc049885r. PubMed DOI

Metzger A., Qin L.Y., Cole A.G., Saionz K.W., Brescia M.R., Gstach H., Wareing J.R., Zimmermann J., Brill W.K.-D., Baldwin J.J., et al. Combined Solution-Phase and Solid-Phase Synthesis of 2-Amino-7,8-Dihydropteridin-6(5H)-Ones. Tetrahedron Lett. 2009;50:7082–7085. doi: 10.1016/j.tetlet.2009.10.005. DOI

Stone S., Wang T., Liang J., Cochran J., Green J., Gu W. Application of Design of Experiments (DoE) Optimisation to the One-Pot Synthesis of 4,6-Dihydropteridinones. Org. Biomol. Chem. 2015;13:10471–10476. doi: 10.1039/C5OB01154J. PubMed DOI

Ishimoto K., Nakaoka K., Yabe O., Nishiguchi A., Ikemoto T. A Practical Chromatography-Free Synthesis of a 5,6-Dihydroimidazolo[1,5-f]Pteridine Derivative as a Polo-like Kinase-1 Inhibitor. Tetrahedron. 2018;74:5779–5790. doi: 10.1016/j.tet.2018.08.020. DOI

Brulikova L., Krupkova S., Labora M., Motyka K., Hradilova L., Mistrik M., Bartek J., Hlavac J. Synthesis and Study of Novel PH-Independent Fluorescent Mitochondrial Labels Based on Rhodamine B. RSC Adv. 2016;6:23242–23251. doi: 10.1039/C5RA20183G. DOI

Brulikova L., Okorochenkova Y., Hlavac J. A Solid-Phase Synthetic Approach to PH-Independent Rhodamine-Type Fluorophores. Org. Biomol. Chem. 2016;14:10437–10443. doi: 10.1039/C6OB01772J. PubMed DOI

Machníková R., Janovská L., Brulíková L. Solid-Phase Synthetic Approach towards New Pyrimidines as Potential Antibacterial Agents. J. Mol. Struct. 2020;1200:127101. doi: 10.1016/j.molstruc.2019.127101. DOI